MENUicon menu


Lentigen is a pioneer in the design, production and clinical application of lentiviral vector-modified cell products. Lentigen has an excellent track record in lentiviral vectors, genetic cell manipulation as CAR T Cell design e.g., and automated cell processing. Selected publications are listed below. For a complete reference list, please contact us.

Lentiviral Vectors
Lentiviral vectors: their molecular design, safety, and use in laboratory and  preclinical research. Dropulic B. Hum Gene Ther. 2011 Jun;22(6):649-57. doi: 10.1089/hum.2011.058. Review. 

Gene transfer in humans using a conditionally replicating lentiviral vector. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B, June CH. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17372-7. 

CAR T Cells
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL. Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. 

T cells expressing CD19 chimeric anitgen receptors for acute lymphoblastic leukemia in children and young adults: a phase I dose escalation trial. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. Lancet. 2015 Feb 7;385(9967):517-28. doi: 10.1016/S0140-6736(14)61403-3.  

Automated Cell Processing
Towards a commercial process for the manufacture of genetically modified T cells for therapy. Kaiser A D, Assenmacher M, Schröder B, Meyer M, Orentas R, Bethke U and Dropulic B. Cancer Gene Therapy. 2015 (22), 72-78 . doi:10.1038/cgt.2014.78